Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Is Altria Group a Buy?

By Rich Duprey - Sep 19, 2018 at 9:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The tobacco giant is facing a lot of obstacles in its path to growth.

After hitting a six-year low this spring, shares of Altria Group ( MO -0.59% ) have clawed their way back, gaining 15% in the process. Although they still trade below their 52-week high and remain well off the all-time high achieved in 2015, the tobacco giant looks like it's making a comeback.

But with cigarette consumption declining and next-generation products facing some difficult hurdles, let's look at whether investors should consider Altria a buy.

Man with green headphones smoking cigarette

Image source: Getty Images.

Maintaining profit

Second-quarter revenue fell 5.4% because cigarette sales net of excise taxes dropped 4.8% to $4.1 billion. Because smokeable products account for 86% of total revenue, any downdraft is going to be magnified.

Yet smokeable products also account for almost all of Altria's operating profit (also 86%), as the tobacco company has made an art out of extracting maximum leverage from this declining business. When taxes on its products are increased, the inelasticity of demand (meaning that smokers continue to pay higher prices for cigarettes) allows Altria to raise prices in response and continue being very profitable.

Still, operating income was down for the second quarter due to declining volumes, particularly with its flagship Marlboro brand, which saw shipment volumes tumble 10% in the period as there was further erosion in its market share. Altria is also getting pressured from the value end of the scale: Its discount segment witnessed an 18.5% plunge in shipments. With other premium brands also down more than 9%, it was an across-the-board rout for the tobacco company.

Hurdles ahead

The Food and Drug Administration (FDA) is also considering proposals like mandating a reduction of nicotine in cigarettes, which Altria says could cost thousands of jobs, along with banning or limiting menthol cigarettes.

It wasn't much better on the smokeless front, either, with total shipments down 2.4% as Skoal dropped over 9%. While its innovative products division (which includes its MarkTen and Green Smoke electronic cigarette brands) saw volumes rise 16% in the quarter, new regulatory concerns are future challenges.

The FDA has warned e-cig manufacturers like Altria, British American Tobacco ( BTI 0.12% ), Imperial Brands ( IMBB.Y 0.85% ), Juul Labs, Philip Morris International ( PM -1.50% ), and Japan Tobacco ( JAPAF -0.96% ) that they need to do a lot more to limit the ability of teenagers to gain access to their products, or the regulatory agency will do it for them -- which might include pulling all their products off store shelves.

It's not an idle threat; the FDA is bringing the hammer down on a number of retailers caught selling e-cigs to underage buyers. Over 1,300 businesses have been warned or fined for failing to enforce the law. So although e-cigs might be a growth avenue for the tobacco companies, they have the potential to hit a roadblock.

Some bright spots

The one area Altria did see some progress in is its wine portfolio. It enjoyed a near-12% jump in revenue net of excise taxes due to higher shipments, helping adjusted operating profits to rise 8% year over year. Unfortunately it is Altria's smallest segment, contributing just $166 million, or 2.6% of the total.

Its 10% stake in Anheuser-Busch InBev ( BUD -1.53% ) also continues to contribute to earnings, some $88 million in the latest period. But that's down year over year due to the brewer's acquisition of SABMiller and some special items A-B took.

The verdict

At 14 times trailing earnings and 16 times this year's estimates, Altria is running below the broad market's valuation but in line with its peers. And considering it's not in a high-growth business (nor a slow-growth one, for that matter), it's tough to say that the tobacco company is undervalued.

However, despite the doubts hovering over its next-gen products, they do offer a glimmer of hope for Altria, particularly if Philip Morris' heat-not-burn product gets marketing approval, as the device will be brought to market under the Marlboro brand.

Also, Altria has shown itself to be a master at extracting profits from its business all the while paying an enticing dividend that yields 5.2% at current prices. Income-seeking investors could certainly benefit with Altria in their portfolio, and even those looking for capital appreciation might find comfort as Altria churns out profitable returns.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Altria Group, Inc. Stock Quote
Altria Group, Inc.
$43.48 (-0.59%) $0.26
Philip Morris International Inc. Stock Quote
Philip Morris International Inc.
$87.35 (-1.50%) $-1.33
Anheuser-Busch InBev SA/NV Stock Quote
Anheuser-Busch InBev SA/NV
$57.36 (-1.53%) $0.89
British American Tobacco p.l.c. Stock Quote
British American Tobacco p.l.c.
$34.32 (0.12%) $0.04
Imperial Brands PLC Stock Quote
Imperial Brands PLC
$21.23 (0.85%) $0.18
Japan Tobacco Inc. Stock Quote
Japan Tobacco Inc.
$19.64 (-0.96%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.